Background When found in the absence of antibodies to extractable nuclear antigens (ENA) or anti-double-stranded DNA (dsDNA) (i.e., monospecific), autoantibodies to the nuclear autoantigen dense fine speckles 70 (anti-DFS70) are purported to rule out SLE. The reported frequency of anti-DFS70 by chemiluminescence (CIA) in SLE is low compared to healthy individuals (0–5.7% vs. 1.3–23.2%), while the frequency of monospecific anti-DFS70 in SLE is even lower at 0–0.4%. There are no studies examining the frequency of anti-DFS70 in an early inception SLE cohort. This study determined the prevalence of anti-DFS70 in a multi-national, multi-ethnic early inception SLE cohort and examined demographic, clinical, and autoantibody associations.

Materials and methods Patients fulfilling ACR Classification Criteria for SLE were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. Demographic and clinical data were collected at enrollment. ANAs were detected by indirect immunofluorescence on Hep-2 cells (ImmuNoConcepts, Sacramento) and ENAs and dsDNA by an addressable laser bead immunoassay (FIDIS Connective13, TheraDia, Paris). Anti-DFS70 antibodies were measured by CIA (Inova Diagnostics, San Diego). The association between anti-DFS70 and baseline demographic, clinical, and autoantibody profiles was assessed using univariate and multivariate logistic regression. For the most informative model, only the remaining statistically significant predictors at the 95% CI: were included, after eliminating other potential predictors individually, starting with the least likely to be associated with the outcome.

Results 1137 patients were included; 89.9% were female and 93.8% were ANA positive (Table 1). The frequency of anti-DFS70 was 7.1% [95% CI: 5.7–8.8%]. 13 of 1137 (1.1%) [95% CI: 0.6–1.9%] were positive for anti-DFS70 only (monospecific). In univariate analysis, patients with musculoskeletal activity (based on SLEDAI items) or anti-β2-glycoprotein-I (anti-β2GP1) were more likely to have anti-DFS70, whereas those with anti-dsDNA, anti-SSA/Ro60, anti-SSB/La, or anti-U1RNP were less likely to have anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odd Ratio (OR) 1.25 [95% CI: 1.10, 1.41]) or anti-β2GP1 (OR 2.15, 95% CI: 1.21, 3.84) were more likely to have anti-DFS70, while those with anti-dsDNA (OR 0.53, 95% CI: 0.31, 0.92) or anti-SSB/La (OR 0.25, 95% CI: 0.08, 0.82) were less likely to have anti-DFS70.

Conclusions The prevalence of anti-DFS70 in newly diagnosed SLE patients was at the high end of the range previously published for SLE (7.1% vs. 0–5.7%) and was associated with musculoskeletal activity and anti-β2GP1. However, ‘monospecific’ anti-DFS70 was rare (1.1%) and is potentially useful to discriminate between ANA positive healthy individuals and SLE.
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with unknown aetiology and a broad clinical expression. One important problem in the management of SLE is the access, and the adherence to drugs, especially in developing countries.

Materials and methods The national public health system (SNSS) covered the health for 73.2% of the Chilean population. Some diseases have been included in a special program of Health Specific Guarantees (GES), in order to assure full access to drugs. SLE was included in this program in 2013 and brings us the opportunity, by first time, to know the number of our patients.

The pharmacy of our hospital has detailed registry of the outpatient prescribed and dispatched medication on SLE patients.

We observed 46 cancers in 46 subjects (with three other subjects reported to have cervical intraepithelial neoplasia, a premalignant condition). At cancer diagnosis, the average age was 51.7 (SD 15.3) years and the average SLE duration was 4.8 (SD 3.1) years. The most common cancer type was breast (n = 9), followed by non-melanoma skin cancer (n = 8, six of which were basal cell), lung (n = 6), prostate (n = 5), four head and neck (tonsillar, tongue, and two oral), cervical (n = 2), thyroid (n = 2), melanoma (n = 2) and one each of Non-Hodgkin lymphoma, leukaemia, multiple myeloma, medulloblastoma brain cancer, renal carcinoma, gastric carcinoid, thymoma, and cutaneous dermatofibrosarcoma. Most of the cancer cases were female (34 cases, 73.9%) and Caucasian (34 cases, 73.9%). Four cancer cases were Hispanic, 4 were black, and 4 were Asian. Twenty of the 46 patients (43.5%) who developed cancers were current (n = 4) or ex-smokers (n = 16); five of the six lung cancers were current (n = 1) or ex-smokers (n = 4).

Conclusions Just under 3% of the incident SLE cohort developed a cancer over an average follow-up of 6.9 years. The most common cancers were breast, non-melanoma skin, and lung cancers. The vast majority of lung cancers were smokers, supporting the belief that lung cancer risk in SLE (as in the general population) is largely driven by smoking. Further analyses will determine the standardised incidence rates for these cancers in SLE, versus the general population.

Acknowledgements We thank all SLICC investigators and their patients for their invaluable data and dedication to SLE research.

Abstract CE-23 Table 1 Frequency of use and average dose of the different SLE medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>Frequency of use (%)</th>
<th>Average dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone</td>
<td>82.1</td>
<td>6.8 mg/day</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>86</td>
<td>233 mg/day</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>25.5</td>
<td>91.6 mg/day</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>21.2</td>
<td>1.750 mg/day</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>14</td>
<td>15.8 mg/week</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>0.9</td>
<td>90 mg/day</td>
</tr>
<tr>
<td>Aspirin</td>
<td>43.2</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Calcium plus</td>
<td>97.4</td>
<td>933 mg/day</td>
</tr>
<tr>
<td>Vitamin D</td>
<td></td>
<td>1.493 IU/day</td>
</tr>
</tbody>
</table>

CE-24

COMPARISON OF SYSTEMIC LUPUS ERYTHEMATOSUS IN 3 DIFFERENT ASIAN ETHNIC GROUPS: RESULTS FROM THE 1000 CANADIAN FACES OF LUPUS COHORT


1Department of Medicine, University of Manitoba, Canada; 2Department of Medicine, CHU de Québec, Université Laval, Canada; 3Department of Paediatrics, McGill University; 4Department of Paediatrics and Child Health, IWK Health Centre, Halifax, Dalhousie University, Canada; 5Department of Medicine, McGill University, Canada; 6Department of Medicine, University of Western Ontario, Canada; 7Department of Paediatrics, University of British Columbia; 8Department of Medicine, The University of Ottawa, Canada; 9Département de Médecine, Université de Montréal, Canada

Background Systemic lupus erythematosus (SLE) is more prevalent and severe in non-Caucasians including Asians. However, Asian ethnicity includes broad geographic, cultural, and genetic diversity. There is limited data examining SLE among North American Asian ethnicities. We describe SLE in 3 Asian subgroups from a large SLE cohort.
CE-22 Cancer in systemic lupus erythematosus: results from the Slicc inception cohort


doi: 10.1136/lupus-2016-000179.101

Updated information and services can be found at:
http://lupus.bmj.com/content/3/Suppl_1/A57

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/